Immuron Ltd (IMRN) Actualités

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron announces record Travelan® sales globally, Australia and USA

Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)  • June 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]